You searched for T cells - Page 19 of 41 - Labiotech.eu

milan top biotechs3 1

Best in Biotech 10 Oct 2017

Buongiorno Biotech! Top 4 Companies Making Milan Europe’s Next Biotech Hub

…things Italian biotech, went as far as to tell me: “The aim should be to produce a few more ‘Genentas’.” The biotech takes on the immunosuppressive environment that a tumor…

October 10, 2017 - 7 minutesmins - By Alex Dale

Pancreatic cancer treatment

In Depth 29 Jan 2025

Pancreatic cancer: Oncolytics Biotech, Candel, and CytomX bring promising therapies to the clinic

…is pancreatic cancer so difficult to treat and what drugs are currently in the therapeutic pipeline? Table of contents Why is pancreatic cancer so difficult to treat? There are several…

January 29, 2025 - 8 minutesmins - By Willow Shah-Neville

European biotech ASCO 2017

News and Trends 7 Jun 2017

What Cancer Therapies did European Biotechs Showcase at ASCO 2017?

…trial, planned to start later this year, that will test whether IO102, a peptide vaccine against the indoleamine 2,3-dioxygenase (IDO) enzyme, can boost the activity of an anti-PD1 checkpoint inhibitor…

June 7, 2017 - 5 minutesmins - By Clara Rodríguez Fernández

t-cell lymphoma

News and Trends 8 Nov 2022

Collaboration to develop CAR-T cell therapy for cutaneous T-cell lymphoma

…treated are reprogrammed to bind specifically to the tumor cells expressing TAG-72. Upon infusion into the patient, the CTH-001 CAR-T cells are expected to destroy the CTCL-associated malignant T cells. …

November 8, 2022 - 3 minutesmins - By Jim Cornall

ADVERTISEMENT

HIV virus Zion

News and Trends 6 Nov 2018

Potential HIV Treatment Shows Early Stage Promise

…the enzyme that HIV uses to insert viral DNA into the host cell’s genome. Integrase then inserts too much viral DNA into the cell, blowing the virus’s cover and making…

November 6, 2018 - 3 minutesmins - By Jonathan Smith

Sangamo TxCell Cover

News and Trends 23 Jul 2018

Sangamo Acquires French Biotech to Develop CAR-T Therapies for Autoimmune Disease

…white blood cells and genetically engineering them to recognize cancer cells. The cells are then reintroduced into the patient, where they attack and kill cancer cells. While most CAR-T-cell therapy…

July 23, 2018 - 3 minutesmins - By Alexander Burik

Tuberculosis research

In Depth 6 Nov 2024

Tuberculosis research: Are we finally close to developing a more effective treatment option?

…when we have the tools to prevent it, detect it, and treat it,” WHO director-general Tedros Adhanom Ghebreyesus told reporters at the time the report was released. Having said that,…

November 6, 2024 - 12 minutesmins - By Willow Shah-Neville

Vironexis

News and Trends 16 Sep 2024

Vironexis’ AAV vector approach: The next frontier in cancer immunology?

…relatively straightforward: use AAV vectors to instruct the liver to secrete a therapeutic protein that guides T cells to recognize and attack cancer cells. This approach not only simplifies the…

September 16, 2024 - 6 minutesmins - By Jules Adam

ovarian cancer

News and Trends 9 Jan 2023

Cartherics granted first patent in China

…other immune cells. The company is also developing autologous CAR-T cell therapies. These use the patient’s own immune system T-cells, which are modified to be effective against the patient’s cancer…

January 9, 2023 - 2 minutesmins - By Jim Cornall

Top biotech companies Oxford

Best in Biotech 17 Sep 2020

The Top 10 Biotech Companies Brewing at Oxford

…goal of exploiting TCR technology in the form of T-cell therapy. The company engineers the TCRs naturally present on the patient’s own immune T cells to improve their ability to…

September 17, 2020 - 8 minutesmins - By Clara Rodríguez Fernández

Biotech companies 2024

Best in Biotech 19 Dec 2023

Nine biotech companies to watch in 2024

…involve precise engineering of cells within the body. This approach is different from traditional methods that typically modify cells outside the body and then reintroduce them. The company’s research targets…

December 19, 2023 - 12 minutesmins - By Jules Adam

Cell Medica CAR NKT cell therapy

News and Trends 1 May 2019

Next-Generation CAR-T Therapy Shows Promise in Child’s Neuroblastoma

…For the therapy tested in this trial, Cell Medica is using the patient’s own cells to manufacture each treatment. In the future, however, the company plans to test an off-the-shelf…

May 1, 2019 - 3 minutesmins - By Clara Rodríguez Fernández